Ryan Fukushima Sells 5,000 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) COO Ryan Fukushima sold 5,000 shares of the business's stock in a transaction dated Monday, July 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the transaction, the chief operating officer owned 145,000 shares in the company, valued at $8,700,000. This trade represents a 3.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, May 20th, Ryan Fukushima sold 7,820 shares of Tempus AI stock. The shares were sold at an average price of $63.21, for a total value of $494,302.20.
• On Tuesday, May 6th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $52.36, for a total value of $1,047,200.00.

Tempus AI Price Performance

Shares of NASDAQ:TEM traded down $2.41 during trading on Friday, hitting $57.19. 6,198,051 shares of the stock were exchanged, compared to its average volume of 7,491,045. The company has a fifty day moving average price of $62.98 and a two-hundred day moving average price of $54.65. The company has a market cap of $9.90 billion and a PE ratio of -7.35. The company has a current ratio of 1.71, a quick ratio of 1.56 and a debt-to-equity ratio of 2.45. Tempus AI, Inc. has a 12-month low of $31.36 and a 12-month high of $91.45.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. The business had revenue of $255.74 million for the quarter, compared to analyst estimates of $248.13 million. Tempus AI had a negative return on equity of 533.21% and a negative net margin of 88.27%. The company's revenue for the quarter was up 75.4% compared to the same quarter last year. On average, analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current year.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cherry Tree Wealth Management LLC purchased a new stake in Tempus AI in the 1st quarter valued at approximately $31,000. University of Texas Texas AM Investment Management Co. purchased a new stake in Tempus AI in the 1st quarter valued at approximately $33,000. Operose Advisors LLC purchased a new stake in Tempus AI in the 4th quarter valued at approximately $25,000. Bartlett & CO. Wealth Management LLC lifted its stake in Tempus AI by 100.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company's stock valued at $39,000 after buying an additional 400 shares in the last quarter. Finally, Nemes Rush Group LLC purchased a new stake in Tempus AI in the 1st quarter valued at approximately $39,000. Hedge funds and other institutional investors own 24.22% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Guggenheim boosted their price target on Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, June 30th. Morgan Stanley lifted their price objective on Tempus AI from $60.00 to $65.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Bank of America lifted their price objective on Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a report on Wednesday, June 25th. Needham & Company LLC reaffirmed a "buy" rating and issued a $70.00 price objective on shares of Tempus AI in a report on Wednesday, May 7th. Finally, BTIG Research assumed coverage on Tempus AI in a report on Monday, April 21st. They issued a "buy" rating and a $60.00 price objective on the stock. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $65.09.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.